March 20, 2019
Vertex Announces Planned Initiation of Phase 2 Studies Evaluating the Next-Generation Correctors VX-440 and VX-152 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis
- VX-440 to be evaluated as part of 4-week triple combination dosing with tezacaftor (VX-661) and ivacaftor; VX-152 to be evaluated as part of 2-week triple combination dosing
- Studies to enroll people with cystic fibrosis who have one copy of the F508del mutation and a minimal function mutation and also people with two copies of the F508del mutation
- Additional next-generation correctors advancing into Phase 1 development; VX-659 Phase 1 clinical study expected to begin in 2016 and will enroll healthy volunteers and CF patients